Centocor's ReoPro/Stent Combination Studies Could Be Attractive To J&J

Centocor's $250 mil. investment in studies to demonstrate the efficacy of its drug ReoPro in combination with coronary stents in percutaneous coronary interventions could be attractive to Johnson & Johnson, which reportedly has been in discussions to acquire the biotech firm.